Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
55.69
+0.47 (0.85%)
At close: Jun 27, 2025, 4:00 PM
55.75
+0.06 (0.11%)
After-hours: Jun 27, 2025, 7:30 PM EDT
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $28.32M in the quarter ending March 31, 2025, a decrease of -88.89%. This brings the company's revenue in the last twelve months to $207.80M, down -34.02% year-over-year. In the year 2024, Protagonist Therapeutics had annual revenue of $434.43M with 624.06% growth.
Revenue (ttm)
$207.80M
Revenue Growth
-34.02%
P/S Ratio
16.64
Revenue / Employee
$1,649,214
Employees
126
Market Cap
3.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PTGX News
- 1 day ago - Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Accesswire
- 7 days ago - Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case - Seeking Alpha
- 26 days ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 5 weeks ago - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - Accesswire
- 7 weeks ago - Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Accesswire
- 2 months ago - Protagonist Therapeutics Reports Granting of Inducement Award - Accesswire
- 3 months ago - Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Accesswire